5 unknown. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Unknown 5 |
Follow Recurrent Cervical Carcinoma: new trials by email Literature Review of Recurrent Cervical Carcinoma trials Research Report on Recurrent Cervical Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tislelizumab and Radiotherapy for Recurrent Cervical Cancer Tislelizumab plus radiotherapy - Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma | Phase 2 | Unknown | Lei Li | 58 | 2022-03-27 | 2022-04-11 |
| Donafenib for Recurrent Cervical Cancer Donafenib combined with paclitaxel and platinum ± PD-1 antibody - Targeted Therapy, Chemotherapy | Phase 2 | Unknown | Lei Li | 20 | 2022-03-27 | 2022-04-04 |
| Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial Anti-PD-1 antibody camrelizumab, Albumin-bound paclitaxel - Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma | Phase 2 | Unknown | Lei Li | 122 | 2022-03-13 | 2022-03-22 |
| Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma Combination of nimotuzumab and radiotherapy - Recurrent Cervical Carcinoma, Radiotherapy | Phase 2 | Unknown | Lei Li | 43 | 2020-12-19 | 2020-12-22 |
| Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas Drug therapy - Chemotherapy, Anti-pd-1 Antibody | Phase 2 | Unknown | Lei Li | 20 | 2020-11-15 | 2020-11-19 |
Uterine Cervical Neoplasms (5) · Drug-Related Side Effects and Adverse Reactions (1)
Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genital Diseases (5) · Genital Diseases, Female (5) · Genital Neoplasms, Female (5) · Neoplasms (5) · Neoplasms by Site (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Uterine Cervical Diseases (5) · Uterine Diseases (5) · Uterine Neoplasms (5) · Chemically-Induced Disorders (1)
Radiotherapy (2) · Albumin-Bound Paclitaxel (1) · Drug Therapy (1) · Paclitaxel (1) · tislelizumab (1)
Lei Li (5)
China (5)
Lei Li, M.D. (5)